Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21309392 | 0.81 | ACLY (0.35) | ACLYKDM4ETDP1CA1CA2 | |
| SCHEMBL21294313 | 0.71 | ACLY (0.41) | ACLYCA1CA2 | |
| SCHEMBL31225892 | 0.69 | TSHR (0.41) | TSHR | |
| SCHEMBL29302972 | 0.69 | GAA (0.36) | KDM4ETDP1TSHRCA1CA2 | |
| SCHEMBL21309701 | 0.68 | ACLY (0.40) | ACLY | |
| SCHEMBL21309395 | 0.68 | — | — | |
| SCHEMBL21309558 | 0.67 | ACLY (0.48) | ACLYKDM4ECA1CA2 | |
| SCHEMBL11513312 | 0.67 | CA1 (0.39) | ACLYTDP1TSHRCA1CA2 | |
| SCHEMBL16473831 | 0.66 | LCK (0.31) | — | |
| SCHEMBL24120682 | 0.66 | KMT2A (0.44) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787837-B2 | DCHBS-active esters of PEG compounds and their use | NOVO NORDISK A/S (DK) | 2023-10-17 | — | — | US | disclosed |
| US-11787837-B2 | DCHBS-active esters of PEG compounds and their use | NOVO NORDISK A/S (DK) | 2023-10-17 | — | — | US | disclosed |
| EP-3534962-B1 | DCHBS-ACTIVE ESTERS OF PEG COMPOUNDS AND THEIR USE | NOVO NORDISK AS (DK) | 2020-08-19 | — | — | EP | disclosed |
| US-20190263854-A1 | DCHBS-ACTIVE ESTERS OF PEG COMPOUNDS AND THEIR USE | NOVO NORDISK A/S (DK) | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263854-A1 | DCHBS-ACTIVE ESTERS OF PEG COMPOUNDS AND THEIR USE | HBB, IAPP, GLP1R | ACLY 181/4885KDM4E 1513/4885TDP1 4759/4885 |
| US-11787837-B2 | DCHBS-active esters of PEG compounds and their use | HBB, IAPP, GLP1R | ACLY 181/4885KDM4E 1513/4885TDP1 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.